The global animal model market was valued at USD 2.91 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 5.99 billion by 2034, registering a CAGR of 8.36% during 2026-2034. North America dominated the market with a 41.8% share in 2025, while Europe is expected to register the fastest CAGR of 9.3%.
Market Size (2025): USD 2.91 Billion
Market Size (2026): USD 3.15 Billion
CAGR (Forecast Period): 8.36%
Forecast Year: 2034
Projected Market Size (2034): USD 5.99 Billion
Dominant Region: North America - 41.8%
Fastest Growing Region: Europe - 9.3% CAGR
Market Overview
Animal models are living organisms used in biomedical research to study disease mechanisms, drug efficacy, safety, pharmacokinetics, and potential therapeutic approaches before treatments advance to human clinical studies. Mice, rats, rabbits, guinea pigs, and other laboratory animals are selected according to specific research requirements.
The market is moving toward more human-relevant and genetically defined research models. Humanized animals are being developed to better reproduce human immune and genetic mechanisms, while AI-based phenotyping is helping researchers automate behavioral and disease assessment and generate more consistent quantitative results.
Growth Drivers
Preclinical drug development remains a major growth driver as pharmaceutical and biotechnology companies use animal models to evaluate candidate therapies for safety, efficacy, pharmacokinetics, and disease mechanisms. Oncology and cardiovascular research programs, among others, rely on specialized laboratory animals to generate preclinical evidence before clinical testing.
Genetically engineered disease models are also strengthening market adoption by allowing researchers to reproduce specific mutations and biological pathways. Customized models can support oncology, rare-disease, immunology, and other specialized research programs where conventional animals may not adequately represent human disease characteristics.
Market Challenges
Specialized animal supply constraints can disrupt research schedules, particularly for nonhuman primates and other highly specialized models. Procurement difficulties and transportation restrictions can raise acquisition costs and delay studies, creating operational pressure for research organizations and suppliers.
Alternative research methods are also reshaping the competitive environment. Organ-on-chip systems, organoids, computational models, and other human-focused approaches are receiving greater regulatory and research attention, encouraging companies in the animal-model ecosystem to diversify their offerings.
Market Opportunities
Veterinary drug development provides an opportunity for animal-model suppliers, animal-health companies, and contract research organizations to expand specialized preclinical services. Study-ready models, breeding programs, safety testing, pharmacokinetic studies, and efficacy packages can create recurring revenue opportunities across veterinary pharmaceutical research.
Vaccine research also creates revenue avenues for model developers and CROs through specialized animals, breeding programs, immune-response studies, and preclinical testing services. Providers with infectious-disease models and integrated study-support capabilities can serve biotechnology companies, vaccine developers, and research institutions.
Segment Analysis
By animal type, the mice segment accounted for a 48.7% share in 2025 and is expected to grow at a CAGR of 9% during 2026-2034. Their established use in biomedical research, genetic similarity to humans, standardized strains, and suitability for disease modeling and drug development support the segment's leading position.
By application, the drug discovery and development segment accounted for a 55.9% share in 2025 and is expected to grow at a CAGR of 9.1% during 2026-2034. Extensive use in preclinical drug testing, safety and efficacy evaluation, disease modeling, and therapeutic-candidate validation supports continued adoption.
By end user, the pharma and biotech companies segment accounted for a 58.6% share in 2025 and is expected to grow at a CAGR of 9% during 2026-2034. Preclinical research programs, drug-development pipelines, and safety testing requirements continue to support the use of standardized and specialized animal models.
Regional Analysis
North America led the animal model market with a 41.8% share in 2025. The U.S. market is being shaped by continued biomedical research funding and a greater focus on human-based research methods, including a planned NIH investment of more than USD 150 million in 2026. Canada is also supporting ethical animal research through USD 7 million in federal funding for 2026-2031 to strengthen animal-care standards.
Europe is projected to register the fastest CAGR of 9.3% during 2026-2034, supported by biomedical research activity and the development of alternative research methods. The U.K. is investing £22 million in 2026 to accelerate non-animal testing approaches, while Germany and France continue to support biomedical research through public funding and life-science programs.
Asia Pacific accounted for 21.4% of the global market in 2025, supported by expanding biomedical research infrastructure and government-backed life-science programs. China, Japan, South Korea, and India remain important markets, with research funding and laboratory-animal development programs supporting regional activity.
Competitive Landscape
The animal model market is moderately fragmented, with specialized animal-model developers, contract research organizations, laboratory-animal suppliers, biotechnology companies, and academic research providers competing across standard, genetically engineered, humanized, disease-specific, and patient-derived models. Established players compete through model quality, genetic characterization, breeding capacity, biosecurity, reproducibility, regulatory support, and global distribution, while emerging companies focus on CRISPR-based development, humanized models, specialized disease models, faster customization, and integrated preclinical services.
Key companies include:
Charles River Laboratories
The Jackson Laboratory
Taconic Biosciences, Inc.
genOway S.A.
Janvier Labs
Harbour BioMed
Crown Bioscience
Envigo RMS, LLC
Inotiv
BIOCYTOGEN
BioSpherix, Ltd.
Ozgene Pty
Transgenic Inc.
Hera Biolabs
B&K Universal
Recent Developments
In June 2026, Charles River Laboratories expanded its preclinical research capabilities through animal-model platforms, genetic models, and translational research services supporting pharmaceutical and biotechnology drug-development programs. In May 2026, The Jackson Laboratory advanced its genetically engineered mouse models and precision-medicine research solutions for disease modeling and biomedical applications.
In April 2026, Envigo, part of Inotiv, expanded its preclinical research capabilities through laboratory animal models, research services, and study-support solutions. In January 2026, Taconic Biosciences expanded its genetically engineered animal-model portfolio through customized research models and breeding technologies targeting oncology, immunology, and drug discovery research.
Future Outlook
The animal model market is expected to maintain steady growth through 2034 as pharmaceutical and biotechnology companies continue using specialized models for preclinical drug development, disease research, and therapeutic validation. Mice, drug discovery and development, and pharma and biotech applications are expected to remain important areas of market activity.
Humanized models, genetically engineered animals, AI-based phenotyping, and specialized disease models are expected to shape product development. At the same time, greater use of organoids, organ-on-chip systems, and computational methods will encourage animal-model providers to focus on human relevance, model customization, reproducibility, and integrated preclinical services.
Click to Read the Complete Insights & Report: https://straitsresearch.com/report/animal-model-market
About Straits Research
Straits Research is a global market intelligence and consulting company providing market research, strategic insights, competitive analysis, and advisory services across multiple industries. The company delivers research and consulting solutions that help businesses understand market dynamics, evaluate competitive environments, identify opportunities, and support informed strategic decisions.
Top comments (0)